NEWPORT BEACH, Calif., March 4 /PRNewswire/ -- Biomerica, Inc.'s
(Nasdaq: BMRA) Chief Executive Officer, Zackary S. Irani, today stressed that
one of the Company's key home test products, the EZ Detect(TM) Colorectal
Disease Test, can play a major role in the current national campaign to reduce
the death rate from colorectal cancer.
"Announcements this week by U.S. health officials indicate that colorectal
cancer is the second leading cause of cancer death and that fewer than one in
five people had a stool-blood test within the last year," Irani said. "Often
the reasons for this are modesty, fear of discomfort or a lack of information.
According to renowned oncologists, colorectal cancer screening is one of the
best, if not the best, cancer prevention strategies we have".
EZ Detect(TM) is a simple, two-minute home test that detects occult
"hidden" blood in the stool, an early warning sign colorectal cancer or other
indications. The test is conducted by simply tossing a biodegradable test pad
directly into the toilet after a bowel movement. If occult blood is present,
a blue-green color appears on the test pad. An appointment with a physician
should be made immediately if the test pad turns blue-green. Unlike other
occult blood tests, no dietary restrictions or stool handling is required. EZ
Detect(TM) was featured this week on NBC Nightly News with Tom Brokaw in a
story about early cancer screening. The product was also shown on the Today
Show.
EZ Detect(TM) costs less than $10 a kit and is readily available at major
chain drug stores nationwide, including CVS Walgreens, Osco and Sav-On. EZ
Detect(TM) is also one of the many products now available at the Company's new
Web site, www.TESTatHOME.com, which markets home medical tests directly to
consumers.
The American Cancer Society predicts this year that 129,400 people in the
U.S. will be diagnosed with colon cancer and 56,000 people will die of it.
Early screening, catching the cancer before it spreads out of the colon or
rectum, could save more than one-third of these lives, which makes the tests
about as effective as mammograms for breast cancer.
Biomerica (Nasdaq: BMRA) is a global medical company devoted to
developing, manufacturing and marketing advanced medical diagnostic products
for the early detection of diseases. The products are used in hospitals,
physician's offices and in the home for self-testing.
Except for historical information contained herein, the statements in this
Press Release are forward-looking statements that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements involve known and unknown risks and
uncertainties which may cause the Company's actual results in future periods
to differ materially from forecasted results. Those risks and uncertainties
include, among other things, the continued demand for the Company's products,
availability of raw materials and the state of the economy. These and other
risks are described in the Company's Annual Report on Form 10-KSB and in the
Company's other filings with the Securities and Exchange Commission.
SOURCE Biomerica, Inc.
-0- 03/04/99
/CONTACT: Investor Relations of Biomerica, Inc., 949-645-2111/
/Web site: testathome.com
(BMRA)
CO: Biomerica, Inc.; American Cancer Society
ST: California
IN: HEA MTC
SU: PDT
*** end of story ***
Regards
A.G. |
